IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex.

Discovery Research, Schering-Plough Biopharma (formerly DNAX Research), Palo Alto, CA 94304, USA.
The Journal of Immunology (Impact Factor: 5.36). 09/2007; 179(4):2551-5. DOI: 10.4049/jimmunol.179.4.2551
Source: PubMed

ABSTRACT IL-33 (IL-1F11) is a recently described member of the IL-1 family of cytokines that stimulates the generation of cells, cytokines, and Igs characteristic of a type 2 immune response. IL-33 mediates signal transduction through ST2, a receptor expressed on Th2 and mast cells. In this study, we demonstrate that IL-33 and ST2 form a complex with IL-1R accessory protein (IL-1RAcP), a signaling receptor subunit that is also a member of the IL-1R complex. Additionally, IL-1RAcP is required for IL-33-induced in vivo effects, and IL-33-mediated signal transduction can be inhibited by dominant-negative IL-1RAcP. The implications of this shared usage of IL-1RAcP by IL-1(alpha and beta) and IL-33 are discussed.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanism of wealing in chronic spontaneous urticaria (CSU) is largely unknown. We previously demonstrated increased expression of Th2 (IL-4 and IL-5) cytokines in skin biopsies from CSU. This suggested that Th2-initiating cytokines (IL-33, IL-25 and TSLP), released through innate immune mechanisms, may play a role in pathogenesis. The aim was to identify Th2-initiating cytokines in lesional and non-lesional skin from CSU patients and to compare results with a control group. Paired biopsies (one from a 4- 8 hour spontaneous weal and one from uninvolved skin) were taken from eight patients with CSU, and nine control subjects, and studied by immunohistochemistry and confocal microscopy. There were increases in IL-4(+) and IL-5(+) cells in lesional skin compared to controls (p=0.03 and p=0.0006, respectively) and marked elevations in the numbers of IL-33(+) , IL-25 (+) and TSLP(+) cells in the dermis of lesional, compared to both non-lesional skin (p=0.002, p=0.01 and p=0.04, respectively) and controls (p=0.001, p=0.0009 and p=0.005, respectively). There was also a correlation between the numbers of IL-33(+) and IL-25(+) cells (r = 0.808, p = 0.015). IL-33 localised to CD31(+) endothelial cells, CD90(+) fibroblasts, CD68(+) macrophages and tryptase(+) mast cells whereas IL-25 was expressed by epithelial cells, mast cells and MBP(+) eosinophils. IL-33 and IL-25 were constitutively expressed in the epidermis of both controls and CSU. Increased expression of Th2-initiating cytokines in lesional skin in CSU suggests that innate pathways may play a role in the mechanism of wealing. Since Th2-initiating cytokines play a role in mast cell activation, inflammation and vascular leakage in CSU, these finding may also have therapeutic implications. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 12/2014; DOI:10.1111/bjd.13621 · 3.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The IL-33/ST2 signaling pathway plays an important role in coronary artery disease (CHD); however, few studies have explored how variants in IL-33/ST2 genes influence CHD risk. Here, we examined the association between genetic variants in IL-33, ST2, and IL-1RAcP of the IL-33/ST2 axis and the risk of CHD. We conducted a case-controlled study with 1146 CHD cases and 1146 age- and sex-frequency-matched controls. Twenty-eight single nucleotide polymorphisms (SNPs) in IL-33, ST2, and IL-1RAcP were genotyped by Sequenom MassArray and TaqMan assay. Logistic regression was used to analyze these associations. The SNP rs4624606 in IL-1RAcP was nominally associated with CHD risk. The AA genotype was associated with a 1.85-fold increased risk of CHD (95% confidence interval (CI) = 1.01-3.36; p = 0.045) compared to the TT genotype. Further analysis showed that AA carriers also had a higher risk of CHD than TT + TA carriers (odds ratio (OR) = 1.85; 95% CI = 1.85-3.35; p = 0.043). However, no significant association was observed between variants in IL-33/ST2 genes and CHD risk. Further studies are needed to replicate our results in other ethnic groups with larger sample size.
    International Journal of Molecular Sciences 01/2014; 15(12):23227-23239. DOI:10.3390/ijms151223227 · 2.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin (IL)-33 signals influence various immune cells during differentiation, immune responses and homeostasis. As discussed in this Review, IL-33 via TI/ST2L regulates the functions of immune cells including T cells, B cells, DCs, macrophages, mast cells, and innate lymphoid cells (ILCs). Stimulation with IL-33 is crucial for CD4+ T cell polarized into Th2 immunity and for the induction of Treg. CD8+ T cells can also express ST2L and IL-33 promotes features of effector CD8+ T cells. For macrophages and ILCs, ST2L presents on these cells and IL-33 induces Th2 cytokine production. IL-33 modulates adhesion, activation, maturation, and cytokine production by mast cells. ST2 is expressed in B1 and is important for differentiation of IL-10-producing B cells. Understanding the specific role of IL-33/ST2L in different immune cells will help to answer the remaining questions that are important for diseases pathologies and intervention strategies by targeting the IL-33/ST2L signals.
    Immunology Letters 02/2015; 179. DOI:10.1016/j.imlet.2015.01.008 · 2.37 Impact Factor

Preview (2 Sources)

1 Download
Available from